<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00770484</url>
  </required_header>
  <id_info>
    <org_study_id>080722</org_study_id>
    <nct_id>NCT00770484</nct_id>
  </id_info>
  <brief_title>Effect of Exercise in OI</brief_title>
  <official_title>Effects of Exercise in Orthostatic Intolerance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main limitation patients with orthostatic intolerance (OI, or postural tachycardia
      syndrome, POTS) have to exercise is related to their increase in heart rate when standing.
      Main pharmacological treatment today is aimed at reducing heart rate with the use of
      betablockers (propanolol), this theoretically could also improve their exercise capacity; if
      their heart rate do not increase as much with the medication, they could exercise more. In
      addition, it has been suggested that in healthy volunteers subjected to head down tilt for 2
      weeks (situation that produces a &quot;simulated&quot; transient POTS-like state) a single bout of
      intense exercise can improve orthostatic tolerance the day after exercising. The mechanisms
      involved in such response are not that clear but could be an increase in plasma volume
      already diminished in POTS patients. It seems likely that the same could be true for POTS
      patients.

      The purpose of the present study are to pharmacologically improve the amount of exercise POTS
      patients can perform by reducing their baseline heart rate (specific aim 1) and to evaluate
      next day heart responses to an acute bout of intense exercise.

      Therefore, the specific aims of this study are:

        1. To test the hypothesis that lowering heart rate response with propanolol will result in
           an increase in exercise capacity.

        2. To test the hypothesis that a single bout of exercise will result in an improvement in
           orthostatic tolerance the day after exercising.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Subjects will be studied twice, once after receiving placebo and in a second occasion
           after receiving propanolol.

        -  An exercise capacity test with estimation of maximal oxygen consumption (VO2 max) will
           be done within 1 hour of receiving a pill containing placebo and that will be in
           appearance identical to the one for propanolol. This test will be conducted on a
           stationary bicycle and the effort will be gradually increased while expired air is
           measured during exhaustive physical work. The test will last approximately 30 minutes
           and be conducted in Vanderbilt's Clinical Trial Center.

        -  The day before and the day after the exercise test subjects will be asked to collect
           urine for 12 hours each time and to keep a record of how much liquid they ingest.

        -  Posture study tests (measurements of heart rate and blood pressure taken while lying
           down and at intervals for up to 30 minutes while standing) will be done the day before
           and the day after the exercise test.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximal Oxygen Consumption Capacity (VO2 Max)</measure>
    <time_frame>Over approximately 30 minutes, within 2 hours of receiving each intervention.</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Orthostatic Intolerance</condition>
  <condition>Postural Tachycardia Syndrome</condition>
  <arm_group>
    <arm_group_label>Propranolol then placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo then propranolol</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol then Placebo</intervention_name>
    <description>Propanolol 20 mg, given orally within 1 hour prior to exercising</description>
    <arm_group_label>Propranolol then placebo</arm_group_label>
    <other_name>Active</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo then Propranolol</intervention_name>
    <description>Placebo, matching pill given orally within 1 hour prior to exercising</description>
    <arm_group_label>Placebo then propranolol</arm_group_label>
    <other_name>Inactive</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meet diagnostic criteria of POTS (Raj, et al., 2005)

          -  Age between 18-65 years

          -  Male and female are eligible (although the majority of patients POTS are female).

          -  Able and willing to provide informed consent

        Exclusion Criteria:

          -  Presence of medical conditions that can explain postural tachycardia (e.g.,
             dehydration, medications)

          -  Pregnancy

          -  Other factors which in the investigator's opinion would prevent the subject from
             completing the protocol.

          -  Patients who are bedridden or chair-ridden.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Italo Biaggioni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 9, 2008</study_first_submitted>
  <study_first_submitted_qc>October 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2008</study_first_posted>
  <results_first_submitted>May 29, 2015</results_first_submitted>
  <results_first_submitted_qc>June 16, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 9, 2015</results_first_posted>
  <last_update_submitted>July 6, 2016</last_update_submitted>
  <last_update_submitted_qc>July 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Italo Biaggioni</investigator_full_name>
    <investigator_title>Professor of Medicine and Pharmacology</investigator_title>
  </responsible_party>
  <keyword>Exercise</keyword>
  <keyword>Propanolol</keyword>
  <keyword>Beta blockers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Postural Orthostatic Tachycardia Syndrome</mesh_term>
    <mesh_term>Orthostatic Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Propranolol Then Placebo</title>
          <description>Active treatment
Propranolol then Placebo: Propanolol 20 mg, given orally within 1 hour prior to exercising</description>
        </group>
        <group group_id="P2">
          <title>Placebo Then Propranolol</title>
          <description>Placebo Treatment
Placebo then Propranolol: Placebo, matching pill given orally within 1 hour prior to exercising</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Propranolol Then Placebo</title>
          <description>Active treatment
Propranolol then Placebo: Propanolol 20 mg, given orally within 1 hour prior to exercising</description>
        </group>
        <group group_id="B2">
          <title>Placebo Then Propranolol</title>
          <description>Placebo Treatment
Placebo then Propranolol: Placebo, matching pill given orally within 1 hour prior to exercising</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31" spread="3"/>
                    <measurement group_id="B2" value="32" spread="2"/>
                    <measurement group_id="B3" value="32" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximal Oxygen Consumption Capacity (VO2 Max)</title>
        <time_frame>Over approximately 30 minutes, within 2 hours of receiving each intervention.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Propranolol</title>
            <description>Active treatment
Propranolol then Placebo: Propanolol 20 mg, given orally within 1 hour prior to exercising</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo Treatment
Placebo then Propranolol: Placebo, matching pill given orally within 1 hour prior to exercising</description>
          </group>
        </group_list>
        <measure>
          <title>Maximal Oxygen Consumption Capacity (VO2 Max)</title>
          <units>mL/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.6" spread="1"/>
                    <measurement group_id="O2" value="24.5" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Propranolol Then Placebo</title>
          <description>Active treatment
Propranolol then Placebo: Propanolol 20 mg, given orally within 1 hour prior to exercising</description>
        </group>
        <group group_id="E2">
          <title>Placebo Then Propranolol</title>
          <description>Placebo Treatment
Placebo then Propranolol: Placebo, matching pill given orally within 1 hour prior to exercising</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Italo Biaggioni, MD., Professor of Medicine and Pharmacology</name_or_title>
      <organization>Vanderbilt University</organization>
      <phone>(615) 936-3420</phone>
      <email>italo.biaggioni@vanderbilt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

